VGXI Blog & News
Welcome to the VGXI blog where we examine scientific trends, innovation, technological advancements in plasmid DNA manufacturing, and uncover how next-generation therapeutics are shaping the future of medicine and improving patients’ lives.
VGXI Completes Successful FDA Inspection Enabling Client BLA Approval Milestone, Advancing Its Leadership in Plasmid DNA Manufacturing
CONROE, Texas — VGXI, Inc., a leading contract development and manufacturing organization (CDMO) specializing in plasmid DNA biopharmaceuticals, including for use in gene therapies, DNA vaccines, and RNA medicines, proudly announces it has recently completed a successful inspection by[…]
Read More
VGXI Selects Cryoport for Biostorage, Bioservices and Supply Chain Solutions to Advance Next-Generation Therapies
Partnership Will Enhance Support for Biopharmaceutical Companies in Developing Cell and Gene[…]
Read More
VGXI to Attend Alliance for Regenerative Medicine Annual Meeting on the Mesa
Conroe, Texas – VGXI, Inc., a leading provider of plasmid DNA manufacturing and development[…]
Read More
VGXI accepted as a Member of the Biopharmaceutical Manufacturing Preparedness (BioMap) Consortium
VGXI, Inc., a leading contract developer and manufacturer (CDMO) specializing in nucleic acid[…]
Read More
VGXI, accepted as a Member of the US Government’s Rapid Response Partnership Vehicle (RRPV)
VGXI, Inc., a leading contract developer and manufacturer (CDMO) specializing in nucleic acid[…]
Read More
Future Proof Your Advanced Therapies Supply Chain with VGXI’s US-Based Plasmid CDMO Expertise
In the current landscape of biopharmaceutical drug development, finding a reliable and[…]
Read More
VGXI Inc. announces a strategic partnership with Sutro Biopharma Inc. to support growing clinical pipeline
VGXI, Inc., a leading contract developer and manufacturer (CDMO) specializing in nucleic acid[…]
Read More
VGXI’s Expanded Manufacturing Capacity Addresses Plasmid DNA Supply Chain Challenges
Plasmid DNA (pDNA) is an essential part of the supply chain for advanced therapies and[…]
Read More
Five Qualities to Look for in a CDMO
As the biopharmaceutical industry increasingly turns to outsourcing, the key to success lies in[…]
Read More
Stephanie Burke Named as VGXI’s New Chief Accounting Officer
Leading plasmid DNA CDMO VGXI, Inc. announces the appointment of Stephanie Burke as its new[…]
Read More